l19il2
mAbexperimentalADC
Clinical trial activity
14 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT01058538)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Melanoma · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Sarcoma, Kaposi · Phase 2
- Skin Neoplasms · Phase 2
Mechanism of action
- FibronectinBINDING AGENT
FN1 binding agent
Immunocytokine. Immunostimulant.
- FibronectinINHIBITOR
FN1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109608 ↗
Also known as
- l19il2
- l19il2
- l19-il2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07228442 | Phase 2 | Dec 31, 2025 | Philogen S.p.A. |
| NCT07227870 | Phase 2 | Dec 31, 2025 | Philogen S.p.A. |
| NCT05329792 | Phase 2 | Jul 1, 2022 | Philogen S.p.A. |
| NCT04362722 | Phase 2 | Jun 1, 2020 | Cantonal Hospital of St. Gallen, Philogen S.p.A. |
| NCT02938299 | Phase 3 | Jul 1, 2016 | Philogen S.p.A., University of Milan, University of Tuebingen |
| NCT02735850 | Phase 2 | Dec 1, 2015 | Catholic University of Sacred Heart, Rome, Karolinska Institute, Katholieke Universiteit Leuven, Maastricht University, Netherlands Cancer Institute, University of Copenhagen, University of Oxford |
| NCT02086721 | Phase 1 | Dec 1, 2015 | Maastricht University |
| NCT02957019 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Philogen S.p.A. |
| NCT02076646 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | Philogen S.p.A., University of Siena, University of Tuebingen |
| NCT02076633 | Phase 2 | Dec 1, 2012 | Philogen S.p.A., University of Milan |
| NCT01253096 | Phase 2 | Apr 1, 2010 | Philogen S.p.A., University of Tuebingen |
| NCT01055522 | Phase 2 | Jun 1, 2008 | Eudax S.r.l., Philogen S.p.A., University of Milan, University of Tuebingen |
| NCT01198522 | Phase 1 | Jun 1, 2007 | Philogen S.p.A. |
| NCT01058538 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2005 | INC Research, Philogen S.p.A., University of Milan |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Philogen S.p.A. | For profit | 12 | 12 | 3 | 2005 |
| University of Milan | Academic/Hospital | 4 | 0 | 2 | 2005 |
| University of Tuebingen | Academic/Hospital | 4 | 0 | 2 | 2008 |
| Maastricht University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Catholic University of Sacred Heart, Rome | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Eudax S.r.l. | For profit | 1 | 0 | 1 | 2008 |
| INC Research | For profit | 1 | 0 | 1 | 2005 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Siena | Academic/Hospital | 1 | 0 | 1 | 2013 |
14 organizations
Page 1 / 1